If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-22. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
=== COVID-19 === The COVID-19 pandemic in 2020 produced a drastic tightening of border controls across the globe. Many countries and regions have imposed quarantines, entry bans, or other restrictions on citizens of, or recent travellers to, the most affected areas. Other countries and regions have imposed global restrictions that apply to all foreign countries and territories, or prevent their own citizens from travelling overseas. The imposition of border controls has curtailed the spread of the virus, but because they were first implemented after community spread was established in multiple countries in different regions of the world, they produced only a modest reduction in the total number of people infected These strict border controls economic harm to the tourism industry through lost income and social harm to people who were unable to travel for family matters or other reasons. When the travel bans are lifted, many people are expected to resume travelling. However, some travel, especially business travel, may decrease in the long term as lower-cost alternatives, such as teleconferencing and virtual events, are preferred. A possible long-term impact has been a decline of business travel and international conferencing, and the rise of their virtual, online equivalents. Concerns have been raised over the effectiveness of travel restrictions to contain the spread of COVID-19.
The exception is the gasoline engine powered unit, which requires a much higher level of training and topside supervision for safe use. The air-line breathing air compressor compresses clean atmospheric air and stores it in a receiver tank, using an overpressure valve to limit the pressure. The air passes through a filter and the air hose to the diver's demand valve. Small 12 volt diaphragm compressors are used for recreational hookah, with a delivery of around 1.8 bars (26 psi), which severely limits the depth to which air can be supplied. The rubber diaphragm pump usually requires no oil lubricant and delivers oil-free air. Piston compressors for hookah deliver air at higher pressures, up to about 9 bars (130 psi), and are usually driven by a small 4-stroke petrol engine. They are usually oil lubricated, using a breathing air rated mineral or synthetic oil without toxic additives. This type of compressor requires a filter to clean the air before delivery to the diver. Delivery pressure for 12 metres (39 ft) is about 20 to 35 pounds per square inch (1.4 to 2.4 bar) using a hookah regulator. Depths of 40 metres (130 ft) require up to 9 bars (130 psi). The pressure relief valve will blow off excess air delivered at low demand, to protect the system from overpressure loads, while delivering sufficient air for higher exertion. The air line hose should be rated for breathing air, with a bore of 8 to 10 millimetres (0.31 to 0.39 in). It is usually buoyant to minimise snagging on the bottom, particularly if not tended from the surface.
From 1999 to 2006, the Michael Power advertising character was the cornerstone of a major marketing campaign to promote Guinness products in Africa. The character, played by Cleveland Mitchell, was portrayed to have been born in Jamaica and raised in Great Britain. By 2003, it became one of the best-known alcohol advertising campaigns in Africa. Jo Foster of the BBC referred to Power as "Africa's very own 'James Bond'".
Israel started evacuating the settlements located close to the border with Lebanon in October 2023 with more than 60 thousand evacuated by April 2024. In the early afternoon of 21 October, several rockets were fired from Lebanon toward the Shebaa Farms; there were no injuries. The IDF conducted a drone strike on the team of militants that launched the rockets. A short while later, anti-tank guided missiles were fired from Lebanon toward Margaliot and Hanita; two foreign workers were injured. The IDF conducted airstrikes against the missile teams. In the evening, another anti-tank guided missile was fired from Lebanon toward Bar'am. One IDF soldier was seriously injured and two others suffered minor injuries. The IDF responded with several airstrikes in southern Lebanon, some of which targeted other missile teams preparing attacks. The IDF conducted airstrikes against two Syrian military positions on 24 October in southwestern Syria, marking the first time the IDF publicly targeted the Syrian military since the Israel–Gaza war began. Hezbollah attacked 19 IDF military sites with missiles and artillery shells and fired one-way attack drones at an IDF position for the first time since the conflict began.
Another strategy for site-specific amine conjugation to proteins is to replace lysine residues with arginine residues (LDVs). If all lysines are depleted then the only remaining free amine is at the amino terminus (N-terminus) of the protein. In the case where the protein is an antibody Fc domain, a recombinant LDV Fc can still be purified using protein A. LDV Fc proteins fused with short peptide targeting sequences can be used to deliver conjugated payloads, including nanoparticles, to specific cell surface proteins. The majority of ADCs under development or in clinical trials are for oncological and hematological indications. This is primarily driven by the inventory of monoclonal antibodies, which target various types of cancer. However, some developers are looking to expand the application to other important disease areas.
Sources: en.wikipedia.org
A few long-lived actinide isotopes, such as 244Pu and 250Cm, cannot be produced in reactors because neutron capture does not happen quickly enough to bypass the short-lived beta-decaying nuclides 243Pu and 249Cm; they can however be generated in nuclear explosions, which have much higher neutron fluxes.
=== A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors === A10BK01 Dapagliflozin A10BK02 Canagliflozin A10BK03 Empagliflozin A10BK04 Ertugliflozin A10BK05 Ipragliflozin A10BK06 Sotagliflozin A10BK07 Luseogliflozin A10BK08 Bexagliflozin A10BK09 Enavogliflozin QA10BK90 Velagliflozin
=== Rest of 2008 === Secretary General of the Council of Europe Terry Davis said on 1 October 2008 that although he was critical of Georgian actions, Georgia was not the aggressor because it did not carry out a military operation against a sovereign state. In late October 2008, French Foreign Minister Bernard Kouchner in his interview with Kommersant said that during the war "there was a real danger of regime change in Georgia". He also said that "...Russia without question was prepared. Russian troops, by some miracle, turned up on the border at the right time." He stated that the next hot spots could become Crimea, Ukraine and others. On 28 October 2008, Brigadier general Mamuka Kurashvili, a Georgian military official, told the parliamentary commission that his "impulsive" description of the military operation as an action "to restore constitutional order" was not sanctioned by superiors and he was "confused" as he had just returned from a battle. He also stated that Russian commander Marat Kulakhmetov's statements that he could not restrain the South Ossetian militants was "a lie." On 29 October 2008, Minister of Internal Affairs of Georgia Vano Merabishvili told Kommersant that "Putin wants to go down in Russian history as collector of lands." He said that the Georgian villages in South Ossetia had to be defended from ethnic cleansing and that from 1 August 2008, Georgians living in South Ossetia "were Kokoity's hostages".
Examples of this category could be relicensing/renewing driver's license, recertifying an analytical balance that has been expired or relocated, and even revalidating professionals. Re-validation may also be conducted when/where a change occurs during the courses of activities, such as scientific researches or phases of clinical trial transitions. Examples of these changes could be sample matrices production scales population profiles and sizes out-of-specification (OOS) investigations, due to the contamination of testing reagents, glasswares, the aging of equipment/devices, or the depreciation of associated assets etc. In GLP accredited laboratories, verification/revalidation will even be conducted very often against the monographs of the Ph.Eur., IP to cater for multinational needs or USP and BP etc to cater for national needs. These laboratories must have method validation as well. Concurrent validation – conducted during a routine processing of services, manufacturing or engineering etc. Examples of these could be duplicated sample analysis for a chemical assay triplicated sample analysis for trace impurities at the marginalized levels of detection limit, or/and quantification limit single sample analysis for a chemical assay by a skilled operator with multiplicated online system suitability testings
Hermann Emil Louis Fischer (German pronunciation: [ˈeːmiːl ˈfɪʃɐ] ; 9 October 1852 – 15 July 1919) was a German chemist and 1902 recipient of the Nobel Prize in Chemistry. He discovered the Fischer esterification. He also developed the Fischer projection, a symbolic way of drawing asymmetric carbon atoms. He also hypothesized the lock and key mechanism of enzyme action. He never used his first given name, and was known throughout his life simply as Emil Fischer.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.